IL-18 is linked to raised IFN-γ in multiple sclerosis and is induced by activated CD4+ T cells via CD40-CD40 ligand interactions

被引:74
作者
Karni, A
Koldzic, DN
Bharanidharan, P
Khoury, SJ
Weiner, HL
机构
[1] Harvard Univ, Brigham & Womens Hosp, Sch Med, Ctr Neurol Dis, Boston, MA 02115 USA
[2] Harvard Univ, Brigham & Womens Hosp, Sch Med, Ctr Neurol Dis, Boston, MA 02115 USA
[3] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Neurol Dis, Boston, MA 02115 USA
[4] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Multiple Sclerosis Ctr, Boston, MA 02115 USA
[5] Harvard Univ, Brigham & Womens Hosp, Sch Med, Multiple Sclerosis Ctr, Boston, MA 02115 USA
基金
美国国家卫生研究院;
关键词
multiple sclerosis; IL-18; IL-12; IFN-gamma; CD40-CD40 ligand interactions;
D O I
10.1016/S0165-5728(02)00018-8
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
We investigated T cell receptor induced IL-18 secretion, the cellular and molecular mechanism, associated with the induction of IL-18 and the role of IL-18 in IFN-gamma production in the different stages of multiple sclerosis (MS). We found that anti-CD3/CD28 induced IL-18 production by peripheral blood mononuclear cells was increased in both relapsing-remitting and secondary progressive MS. In controls and relapsing-remitting MS neutralizing anti-IL-12 and anti-IL-18 alone equally suppressed IFN-gamma production whereas in progressive MS, maximum suppression of IFN-gamma was only observed when neutralizing anti-IL-12 and anti-IL-18 were given together, suggesting that in progressive MS, IL-12 and IL-18 function in a non-linked manner to induce IFN-gamma, Elevated IL-18 production in MS was dependent on the interaction of antigen presenting cells with activated CD4(+) T cells via CD40-CD40 ligand and the levels of IL-18 correlated with disease duration in secondary progressive MS. These results demonstrated that IL-18 has an important role in augmenting Th-1 type immune responses in MS and may be involved in immune changes that occur when patients enter the progressive stage. (C) 2002 Published by Elsevier Science B.V.
引用
收藏
页码:134 / 140
页数:7
相关论文
共 35 条
[1]  
Abbas A K, 1989, Semin Immunol, V1, P5
[2]   Defective regulation of IFNγ and IL-12 by endogenous IL-10 in progressive MS [J].
Balashov, KE ;
Comabella, M ;
Ohashi, T ;
Khoury, SJ ;
Weiner, HL .
NEUROLOGY, 2000, 55 (02) :192-198
[3]   Increased interleukin 12 production in progressive multiple sclerosis: Induction by activated CD4(+) T cells via CD40 ligand [J].
Balashov, KE ;
Smith, DR ;
Khoury, SJ ;
Hafler, DA ;
Weiner, HL .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (02) :599-603
[4]   CCR5+ and CXCR3+ T cells are increased in multiple sclerosis and their ligands MIP-1α and IP-10 are expressed in demyelinating brain lesions [J].
Balashov, KE ;
Rottman, JB ;
Weiner, HL ;
Hancock, WW .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (12) :6873-6878
[5]  
Barbulescu K, 1998, J IMMUNOL, V160, P3642
[6]   Elevated interleukin-12 in progressive multiple sclerosis correlates with disease activity and is normalized by pulse cyclophosphamide therapy [J].
Comabella, M ;
Balashov, K ;
Issazadeh, S ;
Smith, D ;
Weiner, HL ;
Khoury, SJ .
JOURNAL OF CLINICAL INVESTIGATION, 1998, 102 (04) :671-678
[7]   CD40-CD40 ligand interaction in autoimmune disease [J].
Datta, SK ;
Kalled, SL .
ARTHRITIS AND RHEUMATISM, 1997, 40 (10) :1735-1745
[8]   Correlation between interferon production and clinical disease activity in patients with multiple sclerosis [J].
Dettke, M ;
Scheidt, P ;
Prange, H ;
Kirchner, H .
JOURNAL OF CLINICAL IMMUNOLOGY, 1997, 17 (04) :293-300
[9]   Serum interleukin-12 levels in patients with multiple sclerosis [J].
Drulovic, J ;
Mostarica-Stojkovic, M ;
Levic, Z ;
Mesaros, S ;
Stojsavljevic, N ;
Popadic, D ;
Pravica, V .
NEUROSCIENCE LETTERS, 1998, 251 (02) :129-132
[10]   Interferon-γ-inducing factor (IL-18) and interferon-γ in inflammatory CNS diseases [J].
Fassbender, K ;
Mielke, O ;
Bertsch, T ;
Muehlhauser, F ;
Hennerici, M ;
Kurimoto, M ;
Rossol, S .
NEUROLOGY, 1999, 53 (05) :1104-1106